Navigation Links
Pharmacyclics in Medical News

Pharmacyclics Sets Record Date for Rights Offering

.... To participate in the rights offering, shares of pharmacyclics would have to be purchased on or before July 10, 2...the securities laws of any such state. About pharmacyclics Pharmacyclics(R) is a clinical-stage biopharmac...forward the economic interest of its stakeholders. pharmacyclics strives to generate collaborations that allow it t...

Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results

...HDAC, Btk and Factor VIIa Inhibitor programs. pharmacyclics also reported its financial results for the nine m...Laboratoires Servier ("Servier") pursuant to which pharmacyclics granted to Servier an exclusive license for its pa...t for the United States, and will pay a royalty to pharmacyclics on sales outside of the United States....

Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer

...ass and first in class cancer and autoimmune therapeutics." About pharmacyclics Pharmacyclics(R) is committed to creating and developing novel pharma...rnia and is listed on NASDAQ under the symbol PCYC. To learn more about how pharmacyclics advances science to improve human healthcare visit us at http://www.pharma...

Pharmacyclics Receives Nasdaq Notification

... Company will submit its plan to Nasdaq by February 25, 2009. About pharmacyclics Pharmacyclics(R) is committed to creating and developing novel pharm...rnia and is listed on NASDAQ under the symbol PCYC. To learn more about how pharmacyclics advances science to improve human healthcare visit us at http://www.pharma...

Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission

...al Officer and Secretary, in writing at 995 East Arques Avenue, Sunnyvale, California 94085 or by telephone at (408) 774-0330. About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule dr...

Pharmacyclics Reports Third Quarter 2008 Financial Results

...sociated with the Company's HDAC, Btk and Factor VIIa inhibitor programs. pharmacyclics also reported its financial results for the nine months ended March 31, 200...e available on the company's website for one month. About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative products to treat cancer ...

Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results

...o http://ir.pharmacyclics.com . The archived version of the webcast will be available on the company's website for one month. About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule dr...

Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results

...o http://ir.pharmacyclics.com . The archived version of the webcast will be available on the company's website for one month. About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule dr...

Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases

...tases, which are estimated to occur in up to 50% of lung cancer patients. pharmacyclics recently completed patient enrollment in three Phase 2 trials evaluating Xc...linical testing for cancer and autoimmune diseases. About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative products to treat cancer ...
Pharmacyclics in Medical Technology

Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier

... pharmacyclics to maintain all US Rights Conference Call to ...ment of solid tumors and hematologic malignancies. pharmacyclics expects that this alliance will enable it to aggre...t for the United States and will pay a royalty to pharmacyclics on sales outside of the United States....

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

...orders such as rheumatoid arthritis and lupus, and pharmacyclics also has strong preclinical efficacy with PCI-3276...g a proprietary pharmacodynamic assay developed by pharmacyclics to directly assess Btk drug occupancy. Preliminar...derived from the B-cell lymphoma patients. pharmacyclics Btk Presentations at AACR Monday April 20,...

Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.

...YVALE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- pharmacyclics (Nasdaq: PCYC ) announced today the close of a f...mately $1.4 million dollar private investment into pharmacyclics at $0.93/share. Robert Duggan, CEO of pharmacyclics noted, "We appreciate the vote of confidence by th...

Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483

...mation of blood clots). Earlier this year, pharmacyclics presented data at the 2008 Annual Meeting of the A...vity for the Factor VIIa:TF complex. About pharmacyclics Pharmacyclics(R) is committed to creating ...daq under the symbol PCYC. To learn more about how pharmacyclics advances science to improve human healthcare visit...

Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma

... uncontrolled growth of B-cells where activation of the B-cell receptor and Btk signaling are thought to play important roles. About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule dr...

Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma

...chool of Medicine, and lead author of the study. pharmacyclics has been developing MGd for use in combination wit...ociety of Clinical Oncology Annual Meeting (ASCO), pharmacyclics announced final results from a Phase 2 clinical tr...nts. About Motexafin Gadolinium (MGd, Xcytrin) pharmacyclics is developing MGd as an anti-cancer agent with a n...

Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer

... solid tumors, and motexafin gadolinium, which is currently in two Phase 2 trials sponsored by the National Cancer Institute." About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule dr...

Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors

...in 80 percent of the animals, with most achieving partial response. -- pharmacyclics researchers also presented a study identifying biomarkers that may be u... and inflammatory disorders while improving safety. About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative products to treat cancer ...

Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases

...ndidates, demonstrate the breadth of our product portfolio," said Richard A. Miller, M.D., president and CEO of Pharmacyclics. About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule dr...

Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor

...y's lead pan-HDAC inhibitor, PCI-24781, is currently in Phase 1 clinical trials in patients with solid and hematologic tumors. About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and immune mediated diseases. The company is leveraging its small-molecule ...
Pharmacyclics in Biological Technology

Pharmacyclics, Inc. Rights Offering Oversubscribed

...cised by July 31, 2009 have expired. About pharmacyclics Pharmacyclics((R)) is a clinical-stage biopharm...ndard of care in the markets it serves. Presently, pharmacyclics has four product candidates in clinical developmen...in exchange for adding to their product pipelines. pharmacyclics strives to generate collaborations that allow it t...

Pharmacyclics Announces Subscription Price for Rights Offering

...n VP of Finance, at 408-215-3325. About pharmacyclics Pharmacyclics(R) is a clinical-stage biopharm...forward the economic interest of its stakeholders. pharmacyclics strives to generate collaborations that allow it t...and commercialization of its products. Presently, pharmacyclics has four product candidates in clinical developmen...

Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference

...able for replay through June 26, 2009. About pharmacyclics Pharmacyclics(R) is a clinical-stage biopharmac...ndard of care in the markets it serves. Presently, pharmacyclics has four product candidates in clinical developmen...in exchange for adding to their product pipelines. pharmacyclics strives to generate collaborations that allow it t...

Pharmacyclics Files Registration Statement for Rights Offering

...including the repayment of certain indebtedness of pharmacyclics under an existing promissory note in favor of Robe...e up to his proportionate 27% interest and provide pharmacyclics with sufficient capital to satisfy the $6.4 millio...the securities laws of any such state. About pharmacyclics Pharmacyclics(R) is a clinical-stage biopharmac...

Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results

...AC, Btk and Factor VIIa inhibitor programs. pharmacyclics also reported its financial results for the six mo...9 of $500,000. Fiscal 2009 Guidance pharmacyclics projects total operating expenses, excluding share...ss and dedicated employees throughout our Company, pharmacyclics is moving forward to a brighter future." "O...

Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth

...ur Board," said Bob Duggan Chairman and CEO of Pharmacyclics. About pharmacyclics Pharmacyclics(R) is committed to creating and developing novel pharm...rnia and is listed on NASDAQ under the symbol PCYC. To learn more about how pharmacyclics advances science to improve human healthcare visit us at http://www.pharma...

Pharmacyclics Secures $5.0 Million in Debt Financing

... common stock. Under the terms of the loan, pharmacyclics is to pay RWD the principal sum of $5,000,000 on t...t is important to keep in mind that companies like pharmacyclics continue to discover and develop innovative medici...ure in the making at Pharmacyclics." About pharmacyclics Pharmacyclics(R) is committed to creating a...

Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results

...tions I wish to share with my fellow stakeholders. pharmacyclics is a company consisting of high quality people. Mo...viable than ever before. This is our intention. At pharmacyclics we are dedicated to advancing our small molecule c...ed for December 12, 2008." About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative ...

Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results

...due to the completion of preclinical activities. pharmacyclics also reported financial results for the fiscal yea...ties as of June 30, 2007. Fiscal 2009 Guidance pharmacyclics projects total operating expenses, excluding share...llion. Including share-based compensation expense, pharmacyclics projects total operating expenses of between $16 a...

Pharmacyclics Announces It Received Nasdaq Notice of Compliance

...least 10 consecutive business days. Accordingly, Nasdaq has determined that the Company has regained compliance with the Rule. About Pharmacyclics pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and immune mediated diseases. The company is leveraging its small-molecule ...
Other Tags
(Date:8/29/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on sterile convenience surgical packs . , ... convenience surgical packs, by Customed Inc., are recalled ... for the recall is a potential defect found due to ... and infection. The affected products’ manufacture dates were from January ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The Florida ... the Hyatt Regency Orlando last week August 21-24 and ... returned as a presenter. , Dr. Greenstein ... the 21st Century was a standing room session; (2) ... – Doctors of Chiropractic Leading the Way in Injury ...
(Date:8/29/2014)... Canadian Healthy Vending , the largest healthy ... survey of its 200 operators from every region of ... appeal to Canadian consumer seeking refreshment at healthy vending ... five selling healthy snacks and top five selling healthy ... for consumers, employers, and families. Everyone wants to eat ...
(Date:8/29/2014)... 29, 2014 The Department of ... Administration (FDA), Center for Food Safety and Applied ... indefinite quantity (IDIQ) contract and the first two ... “Development, Modernization and Enhancement (DME) for FARM VI” ... , Overarching contract objectives include:, , ...
(Date:8/29/2014)... Under Section 946.300, Qualifications for the Certifying Physician, ... not…advertise in a cultivation center or a dispensing organization.” ... of Illinois has done is create a level of ... their care. The goal is to create a level ... typical prescription medications. Medical steering is a serious issue ...
Breaking Medicine News(10 mins):Health News:Sterile Convenience Surgical Packs by Customed, Inc. Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Sport and Spine Rehab’s CEO Presents at the Florida Chiropractic Association National Convention and Expo 2014 2Health News:Survey Results: What Products Do Canadians Want in Their Healthy Vending Machines? 2Health News:Survey Results: What Products Do Canadians Want in Their Healthy Vending Machines? 3Health News:Team VersaTech and CRGT Win HHS FDA Contract to Support Food Applications Regulatory Management (FARM) System Upgrade 2Health News:Team VersaTech and CRGT Win HHS FDA Contract to Support Food Applications Regulatory Management (FARM) System Upgrade 3Health News:Medical Marijuana Company Provides Solution for Illinois Marketing Regulations 2
(Date:8/28/2014)... million kilometres of new roads will be built worldwide ... Earth,s last wildernesses, where they bring an influx of ... an ambitious study has created a ,global roadmap, for ... balance the competing demands of development and environmental protection. ... that estimates that natural importance of ecosystems and a ...
(Date:8/28/2014)... California, and Alaska totaled 515 million board feet in ... of more than 10 percent compared to the first ... Research Station reported today. During this same period, West ... million board feet. , The total value of these ... $390 million in the same quarter, while the total ...
(Date:8/27/2014)... single fungal cell or bacterial colony exerts on a plant ... role in setting up some of the most fundamental symbiotic ... much of a stretch to say that plants may have ... the touch of beneficial fungi, according to a new study ... University of Wisconsin-Madison. , "Many people have studied how ...
Breaking Biology News(10 mins):Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3West coast log exports up, lumber exports down in second quarter of 2014 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3
Other Contents